Contact this trialFirst, we need to learn more about you.
Checkpoint Inhibitor
Vibostolimab + Pembrolizumab for Advanced Cancer
Recruiting1 awardPhase 1
San Antonio, Texas
This trial is testing a new drug, vibostolimab, for safety and efficacy as a treatment for metastatic solid tumors. The drug will be tested as monotherapy and in combination with pembrolizumab or pembrolizumab plus pemetrexed and carboplatin. The primary hypotheses are that vibostolimab is safe and tolerable when administered at the recommended Phase 2 dose, and that the fixed dose of pembrolizumab/vibostolimab coformulation is safe and tolerable.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.